{"id":"W4399394976","doi":"10.1200/jco.2024.42.16_suppl.5021","title":"Discovery of a novel non-negative matrix factorization (NMF)-based homologous recombination deficiency (HRD) score and subsequent exploration in TALAPRO-2 (TP-2), a phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Baker Hughes (Canada)","funders":"Pfizer","keywords":"Medicine; Enzalutamide; Non-negative matrix factorization; Homologous recombination; Internal medicine; Matrix decomposition; Genetics; Cancer; Gene; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001791966,0.0008003127,0.0007293848,0.0007956473,0.0002468428,0.0004543022,0.0005971575,0.0005436487,0.001212763],"category_scores_gemma":[0.003687492,0.0001630024,0.001225323,0.0003710013,0.0002168263,0.0002878217,0.0004344338,0.0006805602,0.0003777279],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005984047,"about_ca_system_score_gemma":0.001052487,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005765995,"about_ca_topic_score_gemma":0.01086392,"domain_scores_codex":[0.999385,0.0002120641,0.00003278118,0.0002042314,0.0001094215,0.000056567],"domain_scores_gemma":[0.9991884,0.000478024,0.0001230502,0.00004376801,0.00009326932,0.00007352264],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.007354661,0.001945064,0.3467896,0.001551272,0.002356331,0.0007186117,0.0001539861,0.1576223,0.04037179,0.001866662,0.05062586,0.3886439],"study_design_scores_gemma":[0.001111175,0.003120589,0.06165104,0.00007376469,0.0005905051,0.0006030794,0.00006546817,0.9150631,0.008120915,0.002455949,0.007073837,0.00007057045],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9127691,0.002910193,0.05419473,0.001197363,0.0001336333,0.0003967164,0.02495779,0.001611164,0.001829321],"genre_scores_gemma":[0.9206973,0.0003409576,0.03918338,0.0003398641,0.00006967359,0.000272644,0.03822595,0.0000718972,0.0007983809],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005765995,"threshold_uncertainty_score":0.01146489,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1169660990904936,"score_gpt":0.4567513490374288,"score_spread":0.3397852499469352,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}